[go: up one dir, main page]

BRPI0413608A - composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero - Google Patents

composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero

Info

Publication number
BRPI0413608A
BRPI0413608A BRPI0413608-0A BRPI0413608A BRPI0413608A BR PI0413608 A BRPI0413608 A BR PI0413608A BR PI0413608 A BRPI0413608 A BR PI0413608A BR PI0413608 A BRPI0413608 A BR PI0413608A
Authority
BR
Brazil
Prior art keywords
treatment
receptor antagonist
opioid receptor
ligand
prevention
Prior art date
Application number
BRPI0413608-0A
Other languages
English (en)
Inventor
Jotham Wadsworth Coe
Philip Andrew Iredale
Stanton Furst Mchardy
Stafford Mclean
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413608A publication Critical patent/BRPI0413608A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO UM LIGANTE ALFA2DELTA E UM ANTAGONISTA DE RECEPTOR OPIóIDE PARA A PREVENçãO E TRATAMENTO DE DEPENDêNCIA QUìMICA EM UM MAMìFERO". São divulgadas composições farmacêuticas para o tratamento de dependência ou vício em álcool ou cocaína, dependência ou vício em tabaco, redução da síndrome de abstinência de álcool ou auxílio na cessação ou diminuição de uso de álcool e abuso de substancias ou outras dependências comportamentais incluindo jogos de azar. As composições farmacêuticas se compreendem de uma combinação terapeuticamente eficaz de um antagonista de receptor opióide e um ligante alfa2delta e um veículo farmaceuticamente aceitável. O uso destes compostos é também divulgado.
BRPI0413608-0A 2003-08-22 2004-08-09 composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero BRPI0413608A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49737203P 2003-08-22 2003-08-22
PCT/IB2004/002602 WO2005018670A1 (en) 2003-08-22 2004-08-09 Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal

Publications (1)

Publication Number Publication Date
BRPI0413608A true BRPI0413608A (pt) 2006-10-17

Family

ID=34216118

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413608-0A BRPI0413608A (pt) 2003-08-22 2004-08-09 composição farmacêutica compreendendo um ligante alfa2delta e um antagonista de receptor opióide para a prevenção e tratamento de dependência quìmica em um mamìfero

Country Status (6)

Country Link
US (1) US20050043345A1 (pt)
EP (1) EP1658098A1 (pt)
BR (1) BRPI0413608A (pt)
CA (1) CA2535814A1 (pt)
MX (1) MXPA06002024A (pt)
WO (1) WO2005018670A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623412B2 (en) * 2002-09-23 2014-01-07 Elan Pharma International Limited Abuse-resistant pharmaceutical compositions
AU2004275572A1 (en) * 2003-09-25 2005-04-07 Warner-Lambert Company Llc Therapeutic beta aminoacids
US8452656B2 (en) * 2005-06-29 2013-05-28 Google Inc. Prioritizing ad review, by using expected revenue for example, in an advertising system
CA2927527C (en) 2013-11-20 2021-06-01 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof as u-opioid receptor antagonist
US10392345B2 (en) 2015-05-20 2019-08-27 Sanwa Kagaku Kenkyusho Co., Ltd. Crystal of salt of novel 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1242093A1 (en) * 1999-11-06 2002-09-25 Albert Shulman A method of treating substance addiction
US20020187996A1 (en) * 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
BRPI0409307A (pt) * 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives

Also Published As

Publication number Publication date
CA2535814A1 (en) 2005-03-03
EP1658098A1 (en) 2006-05-24
WO2005018670A1 (en) 2005-03-03
MXPA06002024A (es) 2006-05-17
US20050043345A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
Carroll et al. Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist
TR200100241T2 (tr) Nosiseptin reseptörü ORL-1 için yüksek çekim gücü olan ligandlar
RU2428985C2 (ru) Лекарственная форма, содержащая оксикодон и налоксон
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
IS7142A (is) Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
BRPI0507497A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
TR200001942T2 (tr) Opioid agonist/antagonist kombinasyonlar
DE60231911D1 (de) Sedierende und nicht sedierende antihistamine enthaltende zusammensetzungen
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
CA2305799A1 (en) Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
DK0938316T3 (da) Opioidantagonistholdig galenisk formulering
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
NZ563678A (en) Synergistic modulation of FLT3 kinase using 4-cyano-1H-imidazole-2-carboxylic acid{2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}amide and a farnesyl transferase inhibitor
TNSN06278A1 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
HUP0101546A2 (hu) Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére
RU2000126790A (ru) Композиция, предназначенная для лечения алкогольной и лекарственной зависимости, содержащая опиоидный антагонист и модулятор nmda рецепторного комплекса
HUP0003410A2 (hu) Azapoliciklusos vegyületeket tartalmazó kombinációs gyógyszerkészítmények emlősök nikotinélvezetének megelőzésére és kezelésére
RU2010109452A (ru) Способы и композиции, предназначенные для лечения раковых заболеваний
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
WO2001085150A3 (en) Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
JP2009500439A (ja) 疼痛の治療のための相乗的組み合わせ（カンナビノイド受容体アゴニスト及びオピオイド受容体アゴニスト）

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]